摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-formylleurosine | 54022-49-0

中文名称
——
中文别名
——
英文名称
N-formylleurosine
英文别名
methyl (13S,15R,16R,18S)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-8-formyl-10-hydroxy-5-methoxy-10-methoxycarbonyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-18-ethyl-17-oxa-1,11-diazapentacyclo[13.4.1.04,12.05,10.016,18]icosa-4(12),5,7,9-tetraene-13-carboxylate
N-formylleurosine化学式
CAS
54022-49-0
化学式
C46H54N4O10
mdl
——
分子量
822.956
InChiKey
GLDSBTCHEGZWCV-HLTPFJCJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    200-210°C
  • 溶解度:
    可溶于氯仿(少许)、甲醇(少许)

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    60
  • 可旋转键数:
    10
  • 环数:
    10.0
  • sp3杂化的碳原子比例:
    0.57
  • 拓扑面积:
    164
  • 氢给体数:
    2
  • 氢受体数:
    12

SDS

SDS:b2e81cf07a5ae5780d81cd1ecc37cdaf
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-formylleurosine 、 Indole dihydroindole 以 四氢呋喃 为溶剂, 生成 leurosine
    参考文献:
    名称:
    Method of preparing vincristine
    摘要:
    VLB,4'-去氧基乐肾苷,乐肾碱和相关的1-甲基长春烷二聚体在四氢呋喃溶液中被氧化为类长春烷化合物,使用的是含水铬酸-硫酸溶液。
    公开号:
    US04375432A1
点击查看最新优质反应信息

文献信息

  • Synthesis of vinca alkaloids and related compounds, Part XCVI[1] Nitration study of vinblastine-type bisindole alkaloids
    作者:Lajos Szabó、Hedvig Bölcskei、Baitz-Gács Eszter、Marianna Mák、Csaba Szántay
    DOI:10.1002/1521-4184(200112)334:12<399::aid-ardp399>3.0.co;2-1
    日期:2001.12
    The bisindole alkaloids vinblastine, vincristine, and N‐formyl‐leurosine were nitrated and subsequently converted to amino derivatives. In the case of compounds 5e and 5b cytotoxic activity has been found for non‐small cell lung cancer and breast cancer in the concentration range tested (10−5 — 10−9 M). 5b also showed potency in the screen for colon cancer and leukemia.
    双吲哚生物碱长春碱、长春新碱和 N-甲酰基-亮氨酸被硝化并随后转化为氨基衍生物。在化合物 5e 和 5b 的情况下,已在测试的浓度范围 (10-5 — 10-9 M) 中发现对非小细胞肺癌和乳腺癌的细胞毒活性。5b 还在结肠癌和白血病的筛选中显示出效力。
  • Diagnostic/therapeutic agents
    申请人:Klaveness Jo
    公开号:US20050002865A1
    公开(公告)日:2005-01-06
    Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.
    可定位的诊断和/或治疗活性剂,例如超声对比剂,包括悬浮在水载体液中的报告物,该报告物包含含气体或生成气体的材料,该剂能够与目标形成至少两种结合对。
  • Bridged catharanthus alkaloid dimers, their preparation and formulations containing them
    申请人:ELI LILLY AND COMPANY
    公开号:EP0005620A1
    公开(公告)日:1979-11-28
    Novel bridged vinca dimers are described, of the following formula; wherein each R is the same or different residue of an indole-dihydroindole alkaloid of the general formula: wherein R' is OH or O-CO-CH3; R2 is CH3, H or CHO: when taken singly, one of R3 and R4 is H or OH, and the other is C2H5, and R5 is H; and when R4 and R5 are taken together, they form an a-epoxide ring and R3 is C2H5; X is S, O, Se-Se, NH, N-[(CH2)m -CH2-NH-R) or (CH2)p wherein p and each n are 0,1, 2, 3 or 4; and m is 1 or 2; and pharmaceutically-acceptable acid addition salts thereof. The compounds are useful pharmaceuticals especially as oncolytic agents. They are prepared by reacting the corresponding azide of an indole-dihydronidole alkaloid with an appropriate diamine or triamine. Some of the intermediates employed in this preparation are novel, namely those having the structure: R5-NH-CH2-(CH2)n-Q'-(CH2)n-CH2-NH2 where R6 is the group R defined above in which R' is OH and R2 is CH3 or H, and Q' is S, S-S, Q, Se-Se, or (CH2)p where n and p is 0,1,2,3 or 4.
    所述的新型桥接长春花二聚体如下式所示; 其中每个 R 是通式中吲哚-二氢吲哚生物碱的相同或不同残基: 其中 R' 是 OH 或 O-CO-CH3; R2 是 CH3、H 或 CHO: 单个时,R3 和 R4 中的一个是 H 或 OH,另一个是 C2H5,R5 是 H;当 R4 和 R5 合在一起时,它们形成一个环氧化物环,R3 是 C2H5; X 是 S、O、Se-Se、NH、N-[(CH2)m -CH2-NH-R) 或 (CH2)p,其中 p 和每个 n 是 0、1、2、3 或 4;m 是 1 或 2;以及 其药学上可接受的酸加成盐。 这些化合物是有用的药物,特别是作为溶瘤剂。它们是通过吲哚-二氢亚硝基生物碱的相应叠氮化物与适当的二胺或三胺反应制备的。制备过程中使用的一些中间体是新型的,即具有以下结构的中间体: R5-NH-CH2-(CH2)n-Q'-(CH2)n-CH2-NH2,其中 R6 是上面定义的基团 R,其中 R' 是 OH,R2 是 CH3 或 H,Q'是 S、S-S、Q、Se-Se 或 (CH2)p,其中 n 和 p 是 0、1、2、3 或 4。
  • Preparation of bridged catharanthus alkaloid dimers
    申请人:ELI LILLY AND COMPANY
    公开号:EP0033981A2
    公开(公告)日:1981-08-19
    A novel process for preparing a compound of the formula is described wherein each R6 is the residue of an indole-dihydroindole alkaloid of the formula wherein R2 is CH3 or H; when taken singly, one of R3 and R4 is OH or H and the other is C2H5 and R5 is H; and when R4 and R5 are taken together, they form an α-epoxide ring and R3 is C2H5 Q is S-S and each n is 0, 1, 2, 3, 4 which comprises reacting an azide of the formula R6-N3 with a diamine of the formula in the ratio of two moles of R6-N3 per mole of diamine.
    一种制备式化合物的新工艺 其中每个 R6 是式中吲哚-二氢吲哚生物碱的残余物 其中 R2 是 CH3 或 H 当 R3 和 R4 单独存在时,其中一个是 OH 或 H,另一个是 C2H5,R5 是 H;当 R4 和 R5 放在一起时,它们形成一个 α环氧化物环,R3 是 C2H5 Q 是 S-S,每个 n 是 0、1、2、3、4,其中包括使式 R6-N3 的叠氮化物与式 R6-N3 的二胺反应。 以每摩尔二胺对应两摩尔 R6-N3 的比例进行反应。
  • Intermediates used in the preparation of bridged catharanthus alkaloid dimers
    申请人:ELI LILLY AND COMPANY
    公开号:EP0032756A2
    公开(公告)日:1981-07-29
    An intermediate compound useful in the preparation of bridged vinca dimers is described of the formula wherein R6 is an indole-dihydroindole part structure of the formula wherein R2 is CH3 or H; when taken singly, one of R3 and R4 is OH or H and the other is C2H5 and R5 is H; and when taken together R4 and R5 form an a-epoxide ring and R3 is C2H5; and Q' is S, S-S, O, Se-Se, or (CH2)p wherein each n and p is 0, 1 , 2, 3 or 4.
    一种可用于制备桥联长春花二聚体的中间体化合物,其结构式为 其中 R6 是式中的吲哚-二氢吲哚部分结构 其中 R2 是 CH3 或 H 当单独使用时,R3 和 R4 中的一个是 OH 或 H,另一个是 C2H5,R5 是 H;当 R4 和 R5 一起使用时,形成一个环氧化物环,R3 是 C2H5;以及 Q' 是 S、S-S、O、Se-Se 或 (CH2)p,其中每个 n 和 p 是 0、1、2、3 或 4。
查看更多

同类化合物

长春西醇 长春西碱 长春花胺 长春花碱 长春罗定 长春素 长春磷汀 长春甘酯 长春瑞宾 长春氮芥 长春氟宁酒石酸盐 长春氟宁 长春曲醇酸 长春曲醇 长春新碱 长春匹定硫酸盐 脱水长春碱 脱乙酰基长春碱酰肼 硫酸长春碱 硫酸长春新碱 硫酸长春地辛 硫酸长春地辛 甲酰基-环氧长春碱 二(N-亚乙基长春地辛)二硫醚 O4-去乙酰基-3',4'-二去氢-4'-脱氧-C'-去甲长春花碱 N-去甲基长春碱 N-(O-4-去乙酰基-长春碱-23-酰基)-L-亮氨酸乙酯 N-(4-叠氮基-3-碘水杨酰)-N'-beta-氨基乙基长春地辛 4-去乙酰基长春花碱 3-(((2-((4-叠氮基-2-硝基苯基)氨基)乙基)氨基)羰基)-O4-去乙酰基-3-去(甲氧羰基)-长春花碱 3''-(beta-氯乙基)-2'',4''-二氧代-3,5''-螺恶唑烷-4-去乙酰氧基长春碱 2,5-哌嗪二酮,1,4-二甲基-3-亚甲基- (3'a,4'a)-4'-脱氧-3',4'-环氧-12'-羟基-长春花碱 12'-iodovinblastine 12'-thiomethylvinblastine 20',20'-difluoro-4'-deoxyvinblastine methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[(cyclobutanecarbonylamino)methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[[(4-chlorobenzoyl)amino]methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-10-[[(4-methoxybenzoyl)amino]methyl]-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[(3,3-dimethylbutanoylamino)methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-8-methyl-10-[[(4-nitrobenzoyl)amino]methyl]-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-8-methyl-10-[(3-methylbutanoylamino)methyl]-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-[[(4-fluorobenzoyl)amino]methyl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[(butanoylamino)methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[[(3-chlorobenzoyl)amino]methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[(cyclopropanecarbonylamino)methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[[(2-chlorobenzoyl)amino]methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-10-[(2,2-dimethylpropanoylamino)methyl]-12-ethyl-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-8-methyl-10-[(propanoylamino)methyl]-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate methyl (13S,15R)-13-[(1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-10-hydroxy-5-methoxy-8-methyl-10-[(pyridine-4-carbonylamino)methyl]-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-ethyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9,16-pentaene-13-carboxylate